Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.58 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15064842 | 0.85 | HCRTR1 (0.53) | HCRTR1PDE2AHCRTR2CHRM2CCR3 | |
| SCHEMBL16277457 | 0.83 | HCRTR1 (0.67) | HCRTR1PDE2AHCRTR2CHRM2CCR3 | |
| SCHEMBL18735000 | 0.83 | HCRTR1 (0.67) | HCRTR1PDE2AHCRTR2CHRM2CCR3 | |
| SCHEMBL4916902 | 0.82 | HCRTR1 (0.52) | HCRTR1PDE2ACCR3CNR2 | |
| SCHEMBL4916897 | 0.82 | HCRTR1 (0.52) | HCRTR1PDE2ACCR3CNR2 | |
| SCHEMBL20102675 | 0.81 | HCRTR2 (0.47) | HCRTR1PDE2AHCRTR2CHRM2CCR3 | |
| SCHEMBL4919265 | 0.81 | HCRTR1 (0.52) | HCRTR1PDE2ACCR3 | |
| SCHEMBL20111520 | 0.81 | HCRTR2 (0.47) | HCRTR1PDE2AGAAHCRTR2CCR3 | |
| SCHEMBL4919272 | 0.81 | HCRTR1 (0.52) | HCRTR1PDE2ACCR3 | |
| SCHEMBL3570468 | 0.80 | HCRTR1 (0.49) | HCRTR1PDE2ATSHRCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815863-B2 | Hydrogen bond forming fluoro ketolides for treating diseases | CEMPRA PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Q6ZSR9, LSS, LCT | HCRTR1 1570/4885PDE2A 3798/4885GRM5 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.